Highlights
- Chimeric Therapeutics will host an educational webinar on CAR T cell therapies on 18 April.
- The webinar will provide an overview on CAR T cell therapy.
- The webinar will shed light on the background and development of the company’s CAR T cell therapy, CHM 1101.
Clinical-stage cell therapy company Chimeric Therapeutics (ASX: CHM) is set to host an educational webinar on CAR T cell therapies.
The webinar is aimed at providing an overview on CAR T cell therapy. Also, the webinar will spotlight the background and development of CHM 1101, the company’s novel and promising CAR T cell therapy under trials for the treatment of patients with recurrent and progressive glioblastoma.
Moreover, the webinar will cover a corporate update on the company’s other programs, said Chimeric CEO and Managing Director Jennifer Chow.
The webinar will be held on 18 April 2023 at AEST 11 am. Interested parties can click here to register for the webinar.
Chimeric Therapeutics – an Australian leader in cell therapy
Chimeric Therapeutics is an ASX-listed company with mission to bring cellular therapies to life for more patients with cancer. The company is backed by a world-class team of cell therapy pioneers and experts.
Its current pipeline includes CHM 1101 (CLTX CAR T), CHM 2101 (CDH17 CAR T) and CHM 0201 (CORE-NK platform).
Data source: company update
Stock price performance
CHM shares were trading at AU$0.078 in the early hours of trading on the ASX on 11 April 2023, up more than 2.6% from the last close. The company has a market cap of AU$33.21 million.
In the last one-month period, the stock has gained nearly 13%.